Laurus Labs Reports 125% Profit Increase in June 2026 Quarter on CDMO Growth
Laurus Labs reported a 125% rise in consolidated net profit to approximately Rs 368 crore for the June 2026 quarter, with sales increasing 29% to Rs 2,026 crore. Growth was driven by a 67% surge in the CDMO business, particularly the small molecules segment, alongside a 10% rise in generics revenue. The company highlighted strong operating margins and milestones including in-licensing antibody drug conjugates and acquiring land for a new manufacturing facility, reflecting its ongoing portfolio expansion.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 37/100.
Outlets measured: thehindu, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 24 Jul, 10:53 am. Other outlets followed.